Posted on August 22, 2022 in: Member News
The Food and Drug Administration (FDA) on Friday cleared Novavax’s COVID-19 vaccine for emergency use in adolescents, paving the way to expand eligibility for the fourth shot available in the United States.
The two-dose regimen utilizes protein-based technology previously leveraged in vaccines to combat other viruses, offering an alternative for Americans skeptical of Pfizer and Moderna’s mRNA technology.
Providers can begin administering the vaccine to people aged 12 through 17 after a sign off from the Centers for Disease Control and Prevention (CDC), which has already authorized the vaccine’s use for adults. The two doses are given three weeks apart.